2024-515774-27-00招募中4 期
AntiPlatelet theraPy stratEgy followiNg left atrial appenDAGe closurE
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- The primary end point is the number of ischemic lesions appearing on the diffusion sequences and/or FLAIR between cerebral MRI scans performed within 24 hours of the procedure and after 3 months of anti-thrombotic treatment.
研究概览
简要总结
Evaluate the efficacy of 2 different antithrombotic strategies (aspirin VS aspirin + clopidogrel) following LAAC by comparing the occurrence of ischemic lesions on brain MRIs performed within 24h after the procedure (D0) and after 3 months of follow-up.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female patients with LAAC indication according to CNEDiMTS guidelines
- •Age ≥ 18 years
- •Written informed consent provided by the patient
- •Heart team approval: multidisciplinary team including interventional cardiologists, neurologists and other physicians discussing the definitive contraindication for anticoagulation
- •Registration under social security system
排除标准
- •Known hypersensitivity to aspirin and/or clopidogrel - Patients with mastocytosis, in whom the use of acetylsalicylic acid can lead to severe hypersensitivity reactions (including circulatory shocks with flushing, hypotension, tachycardia and vomiting)
- •Known hypersensitivity to aspirin and/or clopidogrel - Severe liver failure
- •Known hypersensitivity to aspirin and/or clopidogrel - Severe kidney failure (Creatinine light < 30ml/min)
- •Known hypersensitivity to aspirin and/or clopidogrel - Uncontrolled severe heart failure
- •Contraindication to MRI: claustrophobia or inability to lie still for exam time, implantable pacemaker or defibrillator, intracorporeal metal foreign body (especially intraocular), intra-ocular metal clipcranial, cochlear implant, cardiac valve prosthesis type Starr-Edwards pre 6000, or biomedical device type insulin pump or neurostimulator.
- •Adults under legal protection (guardianship, curatorship or safeguard of justice)
- •Patient deprived of liberty by judicial or administrative decision,
- •Pregnant or breast-feeding women
- •Woman of childbearing age who does not benefit from highly effective contraception (CTFG recommendation on highly effective contraceptive methods: oral, intravaginal or transdermal estogeno-progestin contraception; progestin-based oral, injectable or implantable contraception; intrauterine device; hormonal intrauterine device; female sterilization (occlusion of the fallopian tubes))
- •Iode contraindication
- •Unacceptable bleeding risk with double antiplatelet therapy decided by the physician who contraindicated oral anticoagulation
- •Patient already participating in another category 1 interventional research
- •Patient in a period of exclusion relative to another research protocol
- •LAAC contraindication : left appendage thrombus
- •Major disease resulting in a life expectancy of < 1 year
- •Severe and inherited bleeding disorder
- •Known hypersensitivity to aspirin and/or clopidogrel - Hypersensitivity to clopidogrel, acetylsalicylic acid, or one of the excipients or other nonsteroidal anti-inflammatory drugs (crossreaction)
- •Known hypersensitivity to aspirin and/or clopidogrel - Asthma or a history of asthma with or without nasal polyps induced by salicyles or substances of close activity, including nonsteroidal antiinflammatory drugs
- •Known hypersensitivity to aspirin and/or clopidogrel - Evolving peptic ulcer or history of gastric hemorrhage or perforation after treatment with acetylsalicylic acid or other nonsteroidal antiinflammatory drugs
- •Known hypersensitivity to aspirin and/or clopidogrel - Any constitutional or acquired haemorrhagic disease
结局指标
主要结局
The primary end point is the number of ischemic lesions appearing on the diffusion sequences and/or FLAIR between cerebral MRI scans performed within 24 hours of the procedure and after 3 months of anti-thrombotic treatment.
The primary end point is the number of ischemic lesions appearing on the diffusion sequences and/or FLAIR between cerebral MRI scans performed within 24 hours of the procedure and after 3 months of anti-thrombotic treatment.
次要结局
- Symptomatic ischemic cerebral events (cerebral infarction and transient ischemic attacks) identified by MRI and systematic neurological examination at D1 and M3, and at any time in the event of a symptomatic event
- Systemic thromboembolic events that will be identified when clinically symptomatic
- Cerebral hemorrhagic events that will be identified by MRI (T2 sequence*) and by systematic neurological examination at D1 and M3, and at any time in the event of a symptomatic event.
- Systemic bleeding events that will be identified when clinically symptomatic
- Neurological deficits and their functional impact, which will be measured with the NIHSS (National Institute of Health Stroke Score) and by the modified Rankin score at each post-implantation assessment time (D1 and M3)
- Cognitive assessment of patients using the Montreal Cognitive Assessment (MoCA) scale at D1 and M3
- Events related to the prosthesis embolization procedure and severe pericardial effusion which will be objectified by clinical evaluation and ultrasound examination
- The presence of thrombus on the prosthesis, the existence of residual leakage and the degree of endothelialization which will be evaluated by cardiac CT scan at 3 months
- Treatment compliance will be assessed at M3 for all patients by accounting for treatments taken compared to those that should have been taken. This compliance will be correlated with thromboembolic and haemorrhagic events in order to define the accountability of the treatment strategy on these events
研究者
Dr Zakaria JALAL
Scientific
Centre Hospitalier Universitaire De Bordeaux
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Dual AntiPlatelet Therapy for Stent Assisted Treatment of Cerebral Aneurysmintracranial aneurysmJPRN-UMIN000022462Kobe City Medical Center General Hospital300
招募中
4 期
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurEAtrial AppendageAnticoagulantsPlatelet Aggregation InhibitorsAtrial FibrillationStrokeNCT04796714University Hospital, Bordeaux60
进行中（未招募）
1 期
ADALAATRIAL FIBRILLATION IN PATIENTS AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC)EUCTR2018-001013-32-ESHOSPITAL CLÍNIC BARCELONA160
已完成
不适用
oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)Coronary Artery DiseaseJPRN-UMIN000006698PO Associations for Establishment of Evidence in Interventions4,598
已完成
不适用
Coronary intervention and optimal AntiPlatelet Therapy-Optical coherence tomography studyJPRN-UMIN000013719Osaka General Medical Center200